The healthcare platform builder has become a link between cancer professionals and patients.
Image credit“Toll Gallery”
Recently, Liangyihui has raised over CNY 100 million in a completed Series C, which was led by Qiming Venture and followed by DT Capital, Redhill Capital, Juhe Capital and Legend Capital. According to a person who is familiar with the financing, the funds are expected to be used on further platform's construction and maintenance.
Founded in 2015, Liangyihui has focused on building a professional platform for cancer discipline, providing the most accessible medical services for patients and the most complete marketing scheme for pharmaceutical enterprises. In order to deal with the current situation of information asymmetry in the field of cancer diagnosis and treatment, the company has built an anti-cancer academic platform and provided a comprehensive learning and IP platform for cancer doctors.
Jue Wang, the founder of Liangyihui, says that cancer has become one of the diseases threatening public health the most; it also has become an area attracting research into new drugs. By connecting pharmaceutical companies, doctors, hospitals and patients, Liangyihui aims to accurately match the demand and supply of all parties in the process of tumor treatment and enable patients to get more accurate diagnoses and better treatment. It is reported that the company has over 200,000 active professional users and 300,000 patient users.